Phase II Study of Ipilimumab, Nivolumab, and Panitumumab in Patients With KRAS/NRAS/BRAF Wild-Type Microsatellite Stable Metastatic Colorectal Cancer Treatment grade 3-4 adverse events included ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results